Warnex Inc.

Warnex Inc.

June 28, 2011 09:21 ET

Warnex: Maturity Dates Extended for Certain Outstanding Debentures

LAVAL, QUEBEC--(Marketwire - June 28, 2011) - Warnex Inc. (TSX:WNX) ("Warnex") announced today that the holders of two of its outstanding debentures have extended the maturity dates of their debentures. This extension has been granted in the context of a broader negotiation by Warnex with its debenture holders for the restructuring of approximately CDN$6.1 million in outstanding debentures.

Crestview Capital Master, LLC has extended the maturity date of a US$333,333 unsecured non-convertible debenture from June 25, 2011, to July 5, 2011.

Persistence Capital Partners has extended the maturity date of a CDN$500,000 unsecured non-convertible debenture from July 2, 2011, to July 5, 2011.

As a result of the foregoing, the aggregate of approximately CDN$6.1 million in outstanding debentures of Warnex now all have maturity dates ranging from July 5, 2011, to July 9, 2011.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex Analytical Services provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex Bioanalytical Services specializes in bioequivalence and bioavailability studies for clinical trials. Warnex Medical Laboratories provides specialized testing for the healthcare industry as well as pharmaceutical and central laboratory services. Warnex PRO-DNA Services offers DNA identification tests for paternity, maternity and other family relationships, as well as for immigration and forensic testing purposes. Warnex has three facilities located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.


Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

Contact Information